COST UTILITY ANALYSIS OF VEDOLIZUMAB VERSUS CONVENTIONAL THERAPY FOR BIOLOGIC-NAIVE, MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE PATIENTS IN CHINA

被引：0
|
作者：
Sheng, Y. [1 ]
Chen, J. [1 ]
Ma, L. [1 ]
Xie, L. [1 ]
Zhao, W. [2 ]
Han, Y. [3 ]
机构：
[1] Takeda China Inc, Beijing, Peoples R China
[2] WPP Hlth Practice, Shanghai, Peoples R China
[3] Sun Yat Sen Univ, Guangzhou, Peoples R China
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PGI8
引用
收藏
页码：S533 / S533
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS COMPARISON OF VEDOLIZUMAB, INFLIXIMAB AND CONVENTIONAL THERAPY FOR THE TREATMENT OF BIOLOGIC-NAIVE, MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS PATIENTS IN CHINA
    Sheng, Y.
    Ma, L.
    Chen, J.
    Xie, L.
    Zhao, W.
    Han, Y.
    VALUE IN HEALTH, 2020, 23 : S533 - S533
  • [2] Early disease efficacy of guselkumab therapy in biologic-naive patients with moderately to severely active Crohn's disease: Post-hoc analysis from the phase 3 GALAXI 2 & 3 studies
    Afzali, A.
    Rubin, D. T.
    Danese, S.
    Rayyan, Y.
    Chen, M.
    Terry, N. A.
    Salese, L.
    Van Rampelbergh, R.
    Yee, J.
    Gomez, M.
    Wan, K. Y. Y.
    Yang, Z.
    Sands, B. E.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i200 - i201
  • [3] Improvements in Work Productivity Loss and Associated Cost Reductions with Ustekinumab and Adalimumab in Biologic-Naive Patients with Moderately-to-Severely Active Crohn's Disease: Results From the SEAVUE Study
    Ding, Zhijie
    Muser, Erik
    Hoops, Timothy
    Izanec, James L.
    Ma, Tony
    Gao, Long-Long
    Gasink, Christopher
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S330 - S330
  • [4] Efficacy of biologic therapies for biologic-naive Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis
    Hibi, Toshifumi
    Kamae, Isao
    Pinton, Philippe
    Ursos, Lyann
    Iwakiri, Ryuichi
    Hather, Greg
    Patel, Haridarshan
    INTESTINAL RESEARCH, 2021, 19 (01) : 53 - +
  • [5] Effectiveness and safety of vedolizumab and infliximab in biologic-naive patients with Crohn's disease: results from the EVOLVE study
    Mantzaris, Gerassimos J.
    Bressler, Brian
    Adsul, Shashi
    Luo, Michelle
    Colby, Chris
    Brett, Neil R.
    Saha, Sumit
    Kamble, Pravin
    Wang, Song
    Yarur, Andres
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2024, 36 (03) : 281 - 291
  • [6] Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn’s Disease
    Andrew P. Yu
    Scott Johnson
    Si-Tien Wang
    Pavel Atanasov
    Jackson Tang
    Eric Wu
    Jingdong Chao
    Parvez M. Mulani
    PharmacoEconomics, 2009, 27 : 609 - 621
  • [7] Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn's Disease
    Yu, Andrew P.
    Johnson, Scott
    Wang, Si-Tien
    Atanasov, Pavel
    Tang, Jackson
    Wu, Eric
    Chao, Jingdong
    Mulani, Parvez M.
    PHARMACOECONOMICS, 2009, 27 (07) : 609 - 621
  • [8] COST-EFFECTIVENESS OF VEDOLIZUMAB COMPARED WITH USTEKINUMAB AS TREATMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE IN THE UNITED STATES
    Zouraq, Azzabi, I
    Wilson, M.
    Hather, G.
    Curtis, R.
    Luo, M.
    Khalid, J. M.
    Minda, K.
    VALUE IN HEALTH, 2017, 20 (05) : A183 - A183
  • [9] Hospitalisations, Flares, and Corticosteroid Use Outcomes in Biologic-Naive Patients with Ulcerative Colitis and Crohn's Disease Initiating Vedolizumab
    Alam, Naufil
    Raluy-Callado, Mireia
    Donaldson, Robert
    Kaviya, Arpeat
    Khalid, Javaria
    INFLAMMATORY BOWEL DISEASES, 2017, 23 : S26 - S27
  • [10] Patient Characteristics and Clinical Outcomes in Biologic-Naive Patients With Crohn's Disease Initiating Vedolizumab Treatment Early Versus Later After Diagnosis
    Haridarshan, Patel
    Mireia, Raluy-Callado
    Ariel, Berger
    Robert, Donaldson
    Sharvari, Bhurke
    Mona, Khalid Javaria
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S8 - S8
12345